Center for Scientific Review; Notice of Closed Meetings, 20486-20487 [2024-06097]
Download as PDF
<![CDATA[
20486
Federal Register / Vol. 89, No. 57 / Friday, March 22, 2024 / Notices
27, 2024, 10:30 a.m. to March 27, 2024,
12:30 p.m., National Institutes of Health,
NIDDK, Democracy II, Suite 7000A,
6707 Democracy Boulevard, Bethesda,
MD 20892 which was published in the
Federal Register on March 14, 2024, 89
FR 18652.
This meeting was amended to change
the start date and end date from 03–27–
2024 to 04–02–2024. The meeting is
closed to the public.
Dated: March 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–06127 Filed 3–21–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Adoptive T Cell
Therapy Products Produced Using a
Pharmacological p38 MitogenActivated Protein Kinase (MAPK)
Inhibitor
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this Notice to Poolbeg Pharma
(UK) Limited, incorporated in the
United Kingdom.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before April 8, 2024 will be
considered.
SUMMARY:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Andrew Burke, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center,
Telephone: (240) 276–5484; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION:
ddrumheller on DSK120RN23PROD with NOTICES1
ADDRESSES:
Intellectual Property
1. United States Provisional Patent
Application No. 62/570,708 filed
October 11, 2017, entitled ‘‘Methods of
Producing T Cell Populations Using P38
VerDate Sep<11>2014
19:15 Mar 21, 2024
Jkt 262001
MAPK Inhibitors’’ [HHS Reference No.
E–002–2018–0–US–01];
2. International Patent Application
No. PCT/US2018/055206 filed October
10, 2018, entitled ‘‘Methods of
Producing T Cell Populations Using P38
MAPK Inhibitors’’ [HHS Reference No.
E–002–2018–0–PCT–02]; and
3. United States Patent Application
No. 16/754,926 filed April 9, 2020,
entitled ‘‘Methods of Producing T Cell
Populations Using P38 MAPK
Inhibitors’’ [HHS Reference No. E–002–
2018–0–US–03].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the Government of the
United States of America.
The prospective exclusive license
territory may be the United States of
America, and the field of use may be
limited to the following:
‘‘The treatment of cancer in humans
using adoptive T cell therapy products
produced through the use of a
pharmacological p38 MAPK inhibitor.’’
The E–002–2018 patent family is
primarily directed to a method of
producing populations of T cells for the
treatment of cancer wherein the cells are
cultured (e.g., expanded) in the
presence of a p38 mitogen-activated
protein kinase (MAPK) inhibitor. In
oncology, many investigational adoptive
cell therapies rely on antigen-specific T
cells isolated from the patient in need
of treatment. However, these cells often
exist in a terminally differentiated and
exhausted state, or enter such a state
following manipulation ex vivo, and are
unable to mount a robust immune
response following reinfusion. Recent
evidence suggests that inhibition of P38
MAPK signaling in T cells during ex
vivo expansion can ameliorate this
performance defect. It is hoped that this
modified cell manufacturing approach
will enhance treatment efficacy. The
exclusive field of use which may be
granted to Poolbeg applies to only
certain T cell manufacturing methods
which rely on pharmacologic P38
MAPK inhibitors. Accordingly, the
proposed scope of rights which may be
conveyed under the license covers a
portion of the possible applications of
E–002–2018.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: March 19, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2024–06128 Filed 3–21–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory Sciences.
Date: April 16, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Ghenima Dirami, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122,
MSC 7814, Bethesda, MD 20892, 240–498–
7546, diramig@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Vascular and Hematology Member
Application Review.
Date: April 17, 2024.
Time: 11:00 a.m. to 3:00 p.m.
E:\FR\FM\22MRN1.SGM
22MRN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 57 / Friday, March 22, 2024 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Aisha Lanette Walker,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–594–3527, aisha.walker@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cardiac Sciences.
Date: April 18, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Abdelouahab Aitouche,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4222,
MSC 7814, Bethesda, MD 20892, 301–435–
2365, aitouchea@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Bacterial Virulence.
Date: April 18, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Bakary Drammeh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 805–P,
Bethesda, MD 20892, (301) 435–0000,
drammehbs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Bacterial Virulence.
Date: April 18, 2024.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Susan Daum, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
Bethesda, MD 20892, 301–827–7233,
susan.boyle-vavra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Disease Control and Applied
Immunology.
Date: April 19, 2024.
Time: 1:00 p.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Jian Wang, Ph.D., M.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218,
MSC 7812, Bethesda, MD 20892, (301) 213–
9853, wangjia@csr.nih.gov.
VerDate Sep<11>2014
19:15 Mar 21, 2024
Jkt 262001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–06097 Filed 3–21–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Biotypes of CNS Complications in People
Living with HIV (P01).
Date: April 17, 2024.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: David W. Miller, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Bethesda, MD 20852–9608, 301–443–9734,
millerda@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: March 18, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–06061 Filed 3–21–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
20487
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Miniaturization and
Automation of Tissue Chip Systems
(MATChS) applications received in response
to RFA–TR–23–017 and RFA–TR–23–018.
Date: May 2, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard,
Bethesda, MD 20892 (Video Assisted
Meeting).
Contact Person: Alumit Ishai, Ph.D.,
Scientific Review Officer, Office of Grants
Management and Scientific Review, National
Center for Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Boulevard, MSC 4874, Bethesda,
MD 20892, (301) 496–9539, alumit.ishai@
nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; NCATS CTSA Training
Grants Review Meeting.
Date: May 21, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard,
Bethesda, MD 20892 (Video Assisted
Meeting).
Contact Person: Nakia C. Brown, Ph.D.,
Scientific Review Officer, Office of Grants
Management and Scientific Review, National
Center for Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Boulevard, MSC 4874, Bethesda,
MD 20892, (301) 827–3484, brownnac@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
E:\FR\FM\22MRN1.SGM
22MRN1
]]>Agencies
[Federal Register Volume 89, Number 57 (Friday, March 22, 2024)]
[Notices]
[Pages 20486-20487]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06097]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Respiratory Sciences.
Date: April 16, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Ghenima Dirami, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122, MSC 7814, Bethesda, MD
20892, 240-498-7546, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Vascular and Hematology Member Application
Review.
Date: April 17, 2024.
Time: 11:00 a.m. to 3:00 p.m.
[[Page 20487]]
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Aisha Lanette Walker, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-594-3527,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cardiac Sciences.
Date: April 18, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Abdelouahab Aitouche, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4222, MSC 7814, Bethesda, MD
20892, 301-435-2365, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Topics in Bacterial Virulence.
Date: April 18, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Bakary Drammeh, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 805-P, Bethesda, MD 20892, (301)
435-0000, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics in Bacterial Virulence.
Date: April 18, 2024.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Susan Daum, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3202, Bethesda, MD 20892, 301-827-7233,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Disease Control and Applied Immunology.
Date: April 19, 2024.
Time: 1:00 p.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Jian Wang, Ph.D., M.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218, MSC 7812, Bethesda, MD
20892, (301) 213-9853, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: March 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-06097 Filed 3-21-24; 8:45 am]
BILLING CODE 4140-01-P
